An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch

References

• DanielsKDaugherryJJonesJCurrent contraceptive status among women aged 15–44: United States, 2011–2013NCHS Data Brief2014173 1 8
   Google Scholar
• RosenbergMJWaughMSMeehanTEUse and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuationContraception1995515 283 2887628201
   PubMed Web of Science ®Google Scholar
• KuhlHPharmacology of estrogens and progestogens: influence of different routes of administrationClimacteric20058suppl l 3 63
   Web of Science ®Google Scholar
• Jung HoffmannCKuhlHIntra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedingsContraception1990424 423 4382147887
   PubMed Web of Science ®Google Scholar
• SidneySCheethamTCConnellFARecent combined hormonal contraceptives (CHSs) and the risk of thromboembolism and other cardiovascular events in new usersContraception2013871 93 10023083525
   PubMed Web of Science ®Google Scholar
• RosenbergMJWaughMSOral contraceptive discontinuation: a prospective evaluation of frequency and reasonsAm J Obstet Gynecol19981793 pt 1 577 5829757954
   PubMed Web of Science ®Google Scholar
• AubenyEBuhlerMColauJCVicautEZadikianMChildsMThe Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptivesEur J Contracept Reprod Health Care200494 267 27715799184
   PubMed Web of Science ®Google Scholar
• PottsROLoboRATransdermal drug delivery: clinical considerations for the obstetrician-gynecologistObstet Gynecol20051055 pt 1 953 96115863530
   PubMed Web of Science ®Google Scholar
• BurkmanRTTransdermal hormonal contraception: benefits and risksAm J Obstet Gynecol20071972 134.e1 134.e617689623
   PubMed Web of Science ®Google Scholar
• SamisoeGTransdermal hormone therapy: gels and patchesClimacteric200474 347 35615799606
   PubMed Web of Science ®Google Scholar
• Van den HeuvelMWvan BragtAJAlnabawyAKComparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptiveContraception2005723 1646 1652
   Web of Science ®Google Scholar
• ElgindyNAMehannaMMMohyeldinSMSelf-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal deliveryInt J Pharm20165011–2 167 17926828671
   PubMed Web of Science ®Google Scholar
• MohyeldinSMMehannaMMElgindyNASuperiority of liquid crystalline cubic nanocarriers as hormonal transdermal vehicle: comparative human skin permeation-supported evidenceExpert Opin Drug Deliv2016138 1049 106427167758
   PubMed Web of Science ®Google Scholar
• GruberDSkřivánekASerraniMLaniusVMerzMA comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized studyContraception2015912 105 11225453582
   PubMed Web of Science ®Google Scholar
• GaoYLiangJLiuJXiaoYDouble-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiolInt J Pharm20093771–2 128 13419463930
   PubMed Web of Science ®Google Scholar
• WildeMIBalfourJAGestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparationsDrugs1995502 364 3958521763
   PubMed Web of Science ®Google Scholar
• BarbosaICFilhoCIFaggionDJrBaracatECProspective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse)Contraception2006731 30 3316371291
   PubMed Web of Science ®Google Scholar
• NelsonALTransdermal contraception methods: today’s patches and new options on the horizonExpert Opin Pharmacother2015166 863 87325800084
   PubMed Web of Science ®Google Scholar
• AbramsLSSkeeDNatarajanJWongFAPharmacokinetic overview of Ortho Evra™/Evra™Fertil Steril2002772 suppl 2 S3 S12
   Web of Science ®Google Scholar
• SriprasertIStanczykFZArcherDFEthinyl estradiol and levonorgestrel in a transdermal contraceptive delivery systemExpert Opin Pharmacother20151612 1901 190926194214
   PubMed Web of Science ®Google Scholar
• HofmannBReineckeISchuettBMerzMZurthCPharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptiveInt J Clin Pharmacol Ther20145212 1059 107025295716
   PubMed Web of Science ®Google Scholar
• WesthoffCLReineckeIBangerterKMerzMImpact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cyclesContraception2014903 272 27924969733
   PubMed Web of Science ®Google Scholar
• BerginkWAssendorpRKloosterboerLvan LierWVoortmanGQvistISerum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulinAm J Obstet Gynecol19901636 pt 2 2132 21372147817
   PubMed Web of Science ®Google Scholar
• OdlindVMilsomIPerssonIVictorACan changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?Acta Obstet Gynecol Scand2002816 482 49012047300
   PubMed Web of Science ®Google Scholar
• BackDJPowerJWinklerUPharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptivesAdv Contracept199394 319 3308147246
   PubMedGoogle Scholar
• ZiemanMGuillebaudJWeisbergEShangoldGAFisherACCreasyGWContraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled dataFertil Steril2002772 suppl 2 S13 S18
   PubMed Web of Science ®Google Scholar